Clinical trials: Psychotic Disorder
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia, Schizoaffective Disorder
Motivation and Skills Support (MASS)
Social impairment contributes to more severe symptoms, higher rates of hospitalization, and increased disability in persons with schizophrenia.
- Trial name
- NCT03404219
- Testing
- Motivation and Skills Support (MASS)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Boston University Charles River Campus
Schizophrenia
Virtual Reality Training for Social Skills in Schizophrenia
Social impairments are core features of schizophrenia that lead to poor outcome. Social skills and competence improve quality of life and protect against stress-related exacerbation of symptoms, while supporting resilience…
- Trial name
- VR-SS (NCT03128099)
- Testing
- Virtual reality social skills training
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia
A Study of LY2140023 in Patients With Schizophrenia
The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
- Trial name
- NCT01307800
- Testing
- LY2140023
- Where
- 13 sites in United States, Mexico and 3 more
- Volunteers
- 567 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia, Psychotic Disorders
A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)
The purpose of this study is to determine if individuals with serious mental illnesses exposed to a patient-centered computerized tool versus printed educational materials have higher rates of screening for the metabolic side…
- Trial name
- NCT00677898
- Testing
- Patient-centered computerized tool, Written educational materials
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Autism
Pediatric Open-Label Extension Study
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have…
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Trial name
- NCT01914393
- Testing
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Where
- 88 sites in United States, Bulgaria and 13 more
- Volunteers
- 702 people
- Sponsor
- Sumitomo Pharma America, Inc.
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
- Trial name
- NCT01892189
- Testing
- Ketamine, TAK-063
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Cigarette Smoking, Schizophrenia
Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness
The overall aim of this study is to test the effect of academic detailing (i.e. provider-level educational intervention focused on evidence-based smoking cessation treatment for those with psychiatric illness) and community…
- Conditions
- Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major
- Trial name
- NCT02845440
- Testing
- Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 1,165 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia.
- Trial name
- NCT03437668
- Testing
- WSE
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Chengappa, K.N. Roy, MD
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Schizophrenia
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of IM olanzapine in patients with schizophrenia is greater than IM placebo by comparing changes from baseline to 2 hours post first IM injection of agitation.
- Trial name
- NCT00640510
- Testing
- Rapid Acting Intramuscular Olanzapine, Isotonic sodium chloride solution
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia is a devastating and complex illness, with multiple symptom and behavioral manifestations. Antipsychotic medications are the mainstay of treatment; however, many patients only partially respond to treatment.
- Trial name
- NCT02118610
- Testing
- L-tetrahydropalmatine (30mg), Sugar pill
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to…
- Trial name
- DMXB-A (NCT00100165)
- Testing
- 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Song-making In a Group (SING) R61
The overarching aim of the proposed work is to align a promising treatment lead - Musical Intervention (MI) - with a promising mechanistic account of psychosis - Predictive Processing.
- Trial name
- SING_R61 (NCT05537428)
- Testing
- Musical Intervention
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Smoking Cessation, Schizophrenia
Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia
This R01 grant describes a randomized, double-blind, placebo-controlled trial of nicotine nasal spray (NNS) as an aid for smoking cessation in 60 individuals with schizophrenia.
- Trial name
- NCT01010477
- Testing
- Nicotine Nasal Spray, Behavioral counseling
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Rutgers, The State University of New Jersey
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia
A Study of Safety and Tolerability in Subjects With Schizophrenia
This is an inpatient, open-label, multiple-dose, multicenter study to evaluate the safety and tolerability of LY2140023 given at doses expected to reflect multiples of the anticipated therapeutic exposure under clinical…
- Trial name
- NCT01354353
- Testing
- LY2140023, Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Denovo Biopharma LLC